2.92
0.09 (3.18%)
| Previous Close | 2.83 |
| Open | 2.81 |
| Volume | 575,387 |
| Avg. Volume (3M) | 318,195 |
| Market Cap | 276,098,048 |
| Price / Earnings (TTM) | 7.68 |
| Price / Sales | 3.72 |
| Price / Book | 2.66 |
| 52 Weeks Range | |
| Earnings Date | 18 May 2026 |
| Profit Margin | -51.27% |
| Operating Margin (TTM) | -367.56% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | -10.70% |
| Total Debt/Equity (MRQ) | 4.85% |
| Current Ratio (MRQ) | 5.09 |
| Operating Cash Flow (TTM) | 49.60 M |
| Levered Free Cash Flow (TTM) | 49.31 M |
| Return on Assets (TTM) | -8.07% |
| Return on Equity (TTM) | -24.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Compugen Ltd. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.12% |
| % Held by Institutions | 17.17% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |